Abstract
We present clinical practice guidelines for the diagnosis and treatment of homozygous familial hypercholesterolaemia (HoFH) in the Middle East region. While guidelines are broadly applicable in Europe, in the Middle East we experience a range of confounding factors that complicate disease management to a point whereby the European guidance cannot be applied without significant modification. Specifically, for disease prevalence, the Middle East region has an established epidemic of diabetes and metabolic syndrome that can complicate treatment and mask a clinical diagnosis of HoFH. We have also a high incidence of consanguineous marriages, which increase the risk of transmission of recessive and homozygous genetic disorders. This risk is further augmented in autosomal dominant disorders such as familial hypercholesterolaemia (FH), in which a range of defective genes can be transmitted, all of which contribute to the phenotypic expression of the disease. In terms of treatment, we do not have access to lipoprotein apheresis on the same scale as in Europe, and there remains a significant reliance on statins, ezetimibe and the older plasma exchange methods. Additionally, we do not have widespread access to anti-apolipoprotein B therapies and microsomal transfer protein inhibitors. In order to adapt existing global guidance documents on HoFH to the Middle East region, we convened a panel of experts from Oman, Saudi Arabia, UAE, Iran and Bahrain to draft a regional guidance document for HoFH. We also included selected experts from outside the region. This panel statement will form the foundation of a detailed appraisal of the current FH management in the Middle Eastern population and thereby provide a suitable set of guidelines tailored for the region.
Keywords: Homozygous familial hypercholesterolaemia, prevalence, diagnosis, treatment, genetics.
Current Vascular Pharmacology
Title:Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel
Volume: 13 Issue: 6
Author(s): Abdullah Al-Ashwal, Fahad Alnouri, Hani Sabbour, Abdulraof Al-Mahfouz, Nasreen Al-Sayed, Maryam Razzaghy-Azar, Faisal Al-Allaf, Khalid Al-Waili, Yajnavalka Banerjee, Jacques Genest, Raul D. Santos and Khalid Al-Rasadi
Affiliation:
Keywords: Homozygous familial hypercholesterolaemia, prevalence, diagnosis, treatment, genetics.
Abstract: We present clinical practice guidelines for the diagnosis and treatment of homozygous familial hypercholesterolaemia (HoFH) in the Middle East region. While guidelines are broadly applicable in Europe, in the Middle East we experience a range of confounding factors that complicate disease management to a point whereby the European guidance cannot be applied without significant modification. Specifically, for disease prevalence, the Middle East region has an established epidemic of diabetes and metabolic syndrome that can complicate treatment and mask a clinical diagnosis of HoFH. We have also a high incidence of consanguineous marriages, which increase the risk of transmission of recessive and homozygous genetic disorders. This risk is further augmented in autosomal dominant disorders such as familial hypercholesterolaemia (FH), in which a range of defective genes can be transmitted, all of which contribute to the phenotypic expression of the disease. In terms of treatment, we do not have access to lipoprotein apheresis on the same scale as in Europe, and there remains a significant reliance on statins, ezetimibe and the older plasma exchange methods. Additionally, we do not have widespread access to anti-apolipoprotein B therapies and microsomal transfer protein inhibitors. In order to adapt existing global guidance documents on HoFH to the Middle East region, we convened a panel of experts from Oman, Saudi Arabia, UAE, Iran and Bahrain to draft a regional guidance document for HoFH. We also included selected experts from outside the region. This panel statement will form the foundation of a detailed appraisal of the current FH management in the Middle Eastern population and thereby provide a suitable set of guidelines tailored for the region.
Export Options
About this article
Cite this article as:
Al-Ashwal Abdullah, Alnouri Fahad, Sabbour Hani, Al-Mahfouz Abdulraof, Al-Sayed Nasreen, Razzaghy-Azar Maryam, Al-Allaf Faisal, Al-Waili Khalid, Banerjee Yajnavalka, Genest Jacques, Santos D. Raul and Al-Rasadi Khalid, Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161113666150827125040
DOI https://dx.doi.org/10.2174/1570161113666150827125040 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Abdominal Aortic Calcification: Clinical Significance, Mechanisms and Therapies
Current Pharmaceutical Design East Meets West in the Search for Alzheimers Therapeutics - Novel Dimeric Inhibitors from Tacrine and Huperzine A
Current Alzheimer Research Membrane Rafts in the Respiratory System
Current Respiratory Medicine Reviews Written Consent to Use the Drug in Children: The Problem of Off-Label Drugs
Current Pharmaceutical Design Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology RNAi in Clinical Studies
Current Medicinal Chemistry Preface
Current Nutrition & Food Science The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Evaluation of Plasma Homocysteine Levels as a Prognostic Factor for the Occurrence of Perioperative Myocardial Infarction in Coronary Artery Bypass Grafting: A Pilot Study
Vascular Disease Prevention (Discontinued) High-Density Lipoprotein: Key Molecule in Cholesterol Efflux and the Prevention of Atherosclerosis
Current Pharmaceutical Design Addiction Liability of Pharmacotherapeutic Interventions in Obesity
Current Pharmaceutical Design Direct Covalent Modification as a Strategy to Inhibit Nuclear Factor-Kappa B
Current Medicinal Chemistry Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Mitochondrial Calcium Signaling as a Therapeutic Target for Alzheimer’s Disease
Current Alzheimer Research The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science Evaluation of Left Ventricular Function in Patients with Coronary Slow Flow by the Dobutamine Stress Echocardiography
Current Medical Imaging Relation of Obesity to Cognitive Function: Importance of Central Obesity and Synergistic Influence of Concomitant Hypertension. The Framingham Heart Study
Current Alzheimer Research Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Current Medicinal Chemistry Dietary Small Molecules and Large-Scale Gene Expression Studies: An Experimental Approach for Understanding their Beneficial Effects on the Development of Malignant and Non-Malignant Proliferative Diseases
Current Medicinal Chemistry